第1筆 /總和 1 筆
/ 1 筆
頁籤選單縮合
題名 | Effects of Mitomycin-C on Retinal Pigment Epithelial Cells in Culture=Mitomycin-C對網膜色素性上皮細胞生長之影響 |
---|---|
作者 | 何正廉; 陳珊霓; 蔡瑞芳; | 書刊名 | 中華民國眼科醫學會雜誌 |
卷期 | 34:3 1995.09[民84.09] |
頁次 | 頁29-35 |
分類號 | 416.746 |
關鍵詞 | 網膜色素性上皮細胞; Mitomycin-C; Retinal pigment epithelium; Proliferative vitreoretinopathy; |
語文 | 英文(English) |
中文摘要 | 以藥物來控制增殖性玻璃體視網膜病變 (PVR),多年來一直是學者們所 研究的課題。我們在用抗癌藥物來抑制增殖性玻璃體視網膜病變時所常遭遇到的 問題是:此藥是否有效?是否對網膜有毒性?以及藥物之技予是否方便可行?而以往 所試驗之藥物均未臻理想。本篇用青光眼手術中廣泛使用之Mitomycir一C在視網 膜方面做新的嘗試。我們將各種不同濃度之Mitomycin-C加入培養中之牛眼網膜 色素性上皮細胞來試驗其抑制效果。結果顯示Mitomycir一C對網膜色素性上皮細 胞之生長有明顯之抑制效果,且依其濃度大小而有不同。濃度即使僅有0.05微克 /毫升也可在培養三天後達到-69之抑制生長的效果。此濃度僅為最大安全劑量之 6.25而已。如此可謂Mitomycin-C是相當安全且有效。此外,只靠點藥水即可在玻 璃體內達到此一濃度 (0.05微克/毫升),而不像5-Fluorouracil那樣,需要反覆地眼 球內注射。所以,基於其有效性,安全性及方便性,Mitomycin-C在增殖性玻璃 體視網膜病變之預防上而言,可謂相當有其可行性。 |
英文摘要 | Pharmacologic therapy of proliferative vitreoretinopathy (PVR) has beenwidely investigated and clinically used. The major problems encounteredin antineoplastic agents as pharmacologic therapy of PVR are the potencyof drugs, retinal toxicity and the delivery systems. Many antiproliferativeagents have been tested but are still not satisfying enough. Mitomycin-C,one of the most important drugs in adjunctive therapy of glaucoma filteringsurgery, has not been tested in the vitreoretinal field yet. We used thebovine retinal pigment epithelial cells (RPE) in culture to test the effect ofMitomycin-C. RPE were exposed to various concentrations of Mitomycin-C to see the inhibitory effect of Mitomycin-C on them. The result revealedthat the Mitomycin-C inhibits the proliferation of RPE in culture in a dose-dependent manner. Concentration as low as 0.05 ug/ml can achieve asignificant inhibition (-69) after 3 days of incubation. This is just 6.25 ofthe maximal nontoxic dose. Mitomycin-C is, therefore, potent and safe inthe inhibition of RPE growth. Besides, this concentration (0.05 ug/ml) canbe acheived by topical eyedrops or sponge application only, instead of byrepeated intraocular injections as used for the delivery of 5-fluorouracil.The efficacy, safety and feasibility of Mitomycin-C make it promising in theprevention of proliferative vitreoretinopathy. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。